Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

241.31
+1.240.52%
Pre-market: 241.310.00000.00%07:35 EDT
Volume:424.47K
Turnover:101.82M
Market Cap:15.66B
PE:16.50
High:241.44
Open:238.38
Low:236.00
Close:240.07
52wk High:266.38
52wk Low:123.88
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.60
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.26
PE(LYR):-41.32

Loading ...

RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 27

FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

MT Newswires Live
·
Aug 27

Jazz Pharmaceuticals is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 27

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals price target raised to $281 from $264 at Truist

TIPRANKS
·
Aug 26

Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes Due 2032 and Concurrent Ordinary Share Repurchases

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Initial Purchasers May Buy up to $150 Mln Additional Notes

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Expects to Repurchase up to $225 Mln of Ordinary Shares Concurrently

THOMSON REUTERS
·
Aug 26

Jazz Pharmaceuticals - Net Proceeds from Offering Expected to be Used for General Corporate Purposes

THOMSON REUTERS
·
Aug 26

Piper Sandler Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Aug 26

RBC Adjusts Price Target on Jazz Pharmaceuticals Public to $277 From $273, Maintains Outperform Rating

MT Newswires Live
·
Aug 26

Jazz Pharmaceuticals Highlights Ziihera Launch, Targets $3-$5 Billion Zanidatamab Peak Sales Opportunity

Reuters
·
Aug 26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX)

TIPRANKS
·
Aug 26

U.S. Research Roundup- Intuit, MongoDB, Zscaler

Reuters
·
Aug 26

Jazz Pharmaceuticals Plc : Truist Securities Raises Target Price to $281 from $264

THOMSON REUTERS
·
Aug 26

Jazz Pharma Says FDA Approves Ziihera Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

Reuters
·
Aug 25

Jazz Pharmaceuticals - Ziihera U.S. Prescribing Information Includes Boxed Warnings for Diarrhea and Embryo-Fetal Toxicity

THOMSON REUTERS
·
Aug 25

U.S. FDA Approves Ziihera® (Zanidatamab-Hrii) with and Without Tislelizumab Plus Chemotherapy in First-Line Her2+ Advanced Gastroesophageal Adenocarcinoma

THOMSON REUTERS
·
Aug 25

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22